The week of July 20 to July 26 finally produced one clean handoff from paperwork to public trading, but the broader calendar still looked selective. Scribe Therapeutics priced an upsized IPO at $15 a share for 8.58 million shares, above the 7.2 million shares at $13 to $15 in its amended S-1, and traded sharply higher in its Nasdaq debut. Around that exit, two large consumer names, Jersey Mike's and Reformation, launched roadshows with enough scale to matter. Below them, the rest of the week leaned more defensive: Ticketplus cut terms, Narragansett Bancorp kept working through a mutual-conversion sale, and K2 Capital Acquisition II arrived with a sector-specific SPAC pitch rather than a broad reopening signal.
Scribe was the week's only clear proof that investors will still meet a credible new issue with real demand. The company not only priced at the top of its range, it also added a concurrent private placement of 500,000 shares, or $7.5 million, to Sanofi. Its amended filing showed a biotech still early in commercialization, with the lead wholly owned cardiovascular and metabolic programs only targeting Phase 1 starts beginning in 2027, so IPOGrid reads the reception less as a risk-on call across small biotech and more as a vote for syndicate quality, familiar backers, and a financing story investors could underwrite quickly.
Jersey Mike's was the week's biggest test of whether size can still clear on a mixed tape. The chain's launch materials and SEC filing put the deal at 43.48 million Class A shares at $21 to $25. Of those, 13.78 million are primary shares sold by the company, while 29.70 million come from selling stockholders. The filing also lays out management's ambition to grow from roughly today's footprint to about 7,500 U.S. stores and 15,000 globally over time. That gives the story obvious scale, but our interpretation is that the underwriting challenge is not awareness. It is whether public investors want to fund a debt paydown and expansion plan while a large portion of the cash-out goes to existing holders rather than into the operating business.
Reformation looked cleaner on brand and simpler on terms, but not necessarily cheap in context. The roadshow launched at 14.06 million shares at $15 to $17, with the company selling 9,478,821 shares and selling stockholders adding 4,583,679 more. The same filing says Reformation will not receive proceeds from the selling-stockholder portion. That is not unusual, but it does matter for framing. IPOGrid would frame Reformation as a real consumer growth candidate, not a placeholder filing, yet the public market is still being asked to absorb a fashion name whose prospectus spends real time on tariff effects, supply-chain shifts, and a July tariff refund. That can still work, but it is a tougher handoff than the label's brand heat might imply.
The smaller end of the calendar remained harder to read as genuine momentum. Narragansett Bancorp's original S-1 described a best-efforts, $10 per share bank-conversion sale of up to 7.91 million shares, while the July 23 amendment and supplement referenced participation interests tied to up to 6.71 million shares. The reviewer would treat that as another sign that even community-bank conversions are still being managed with sizing discipline first. Ticketplus made the signal even plainer. Its filing reset the deal to 1.875 million shares at $8 to $10, down from 1.8 million shares at $13 to $15, a 33% cut in midpoint proceeds. For a Latin American ticketing platform that had been pitching geographic expansion and software investment, that is the sort of revision that keeps a deal alive without proving broader appetite.
Two more names rounded out the tone of the week. K2 Capital Acquisition II filed for $150 million by offering 15 million units at $10, each with one share and one right to receive one-tenth of a share at the business combination, aimed at defense, critical infrastructure, energy security, and related sectors. That looks more like thematic sponsor marketing than proof that generic SPAC issuance has reopened. And Lannister Mining was still trying to place 3 million units at a $5 midpoint for $15 million, while Tong Ying Group amended again without public pricing terms in the review-week filing materials. That cluster does not read like a market broadening out. It reads like the usual small-cap cleanup work continuing in the background.
The week's bottom line is straightforward. Scribe gave the market one usable benchmark because it moved from amendment to pricing to trading with real demand behind it. Jersey Mike's and Reformation gave investors two sizable consumer tests that should tell the calendar more about valuation tolerance over the next several weeks. Everything underneath still looks conditional. Until more issuers can price without trimming ambition, IPOGrid's read is that the market is reopening by exception, not by default.